Infections Associated With the Use of Alemtuzumab

This study has been completed.
Sponsor:
Collaborators:
National Taiwan University Hospital
Dr Cipto Mangunkusumo General Hospital
Asan Medical Center
Soon Chun Hyang University
Chonnam National University
Chonbuk National University
Chulalongkorn University
Queen Mary Hospital, Hong Kong
Yonsei University
Kyungpook National University
Information provided by (Responsible Party):
Won Seog Kim, Samsung Medical Center
ClinicalTrials.gov Identifier:
NCT01315457
First received: March 13, 2011
Last updated: May 22, 2012
Last verified: May 2012

March 13, 2011
May 22, 2012
April 2009
March 2012   (final data collection date for primary outcome measure)
Infectious event [ Time Frame: one year ] [ Designated as safety issue: Yes ]
Any infectious complication occurred within one year after the use of alemtuzumab
Same as current
Complete list of historical versions of study NCT01315457 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Infections Associated With the Use of Alemtuzumab
Asian Multinational Retrospective Analysis for Infectious Complications in Patients Treated With Alemtuzumab

The aim of this study is to propose infection prophylaxis from Asian multinational retrospective analysis of infectious complications in patients who were treated with alemtuzumab

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample

Patients received alemtuzumab as a treatment for hematologic malignancy

Patients Treated With Alemtuzumab
Not Provided
Alemtuzumab
Patients treated with alemtuzumab
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
182
March 2012
March 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients received alemtuzumab as a treatment for hematologic malignancy ex. non-Hodgkin lymphoma Acute myeloid leukemia Aplastic anemia

Exclusion Criteria:

  • Patients did not receive alemtuzumab
Both
15 Years to 90 Years
No
Contact information is only displayed when the study is recruiting subjects
Thailand,   Indonesia,   Taiwan,   China,   Korea, Republic of
 
NCT01315457
2009-03-006
No
Won Seog Kim, Samsung Medical Center
Samsung Medical Center
  • National Taiwan University Hospital
  • Dr Cipto Mangunkusumo General Hospital
  • Asan Medical Center
  • Soon Chun Hyang University
  • Chonnam National University
  • Chonbuk National University
  • Chulalongkorn University
  • Queen Mary Hospital, Hong Kong
  • Yonsei University
  • Kyungpook National University
Principal Investigator: Won Seog Kim, MD, PhD Samsung Medical Center
Samsung Medical Center
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP